R. Zheng

发表

Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition

S. Qin, Yan Yang, Hao Liu, 2013, Oncology reports.

Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis

R. Zheng, Danna Wang, Xiaomeng Gong, 2015, World Journal of Surgical Oncology.

[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

Cheng Huang, Shucai Zhang, S. Jiao, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Thioaptamer conjugated single-wall carbon nanotubes in human breast cancer targeted photothermal therapy in-vivo and in-vitro

Xiao Han, R. Zheng, Shiwu Wu, 2016 .

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Ying Cheng, Y. Ba, Jianming Xu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients

J. Fang, X. Li, Y. Shu, 2019, Journal of Thoracic Oncology.

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

Jingdong He, K. Nan, Jian-hua Chang, 2020, Annals of translational medicine.

Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1

C. Ling, Qiang Chen, Z. Meng, 2005 .

Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma

Yan Yang, Qiong Wu, R. Zheng, 2016, Oncology letters.

Xuebijing Protects Rats from Sepsis Challenged with Acinetobacter baumannii by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion

Yan Yang, Qiong Wu, R. Zheng, 2013, Evidence-based complementary and alternative medicine : eCAM.

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

T. Wang, Yanqiu Zhao, Jianying Zhou, 2023, BMC Medicine.

Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer.

Yan Yang, Fen Yang, R. Zheng, 2020, International journal of clinical and experimental pathology.

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes

Yan Yang, R. Zheng, Zishu Wang, 2017, Medical science monitor : international medical journal of experimental and clinical research.

Baicalein inhibits hepatocellular carcinoma cells through suppressing the expression of CD24.

Xiao Han, R. Zheng, Shiwu Wu, 2015, International immunopharmacology.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

Circ_0085495 knockdown reduces adriamycin resistance in breast cancer through miR-873-5p/integrin β1 axis

R. Zheng, Hua-Xia Xie, 2021, Anti-cancer drugs.

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Ying Cheng, Jianming Xu, Yunpeng Liu, 2019, Cancer communications.

Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of recombinant human lymphotoxin‐α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open‐label, controlled, phase 2b trial

Yun Wang, Fenghua Wang, Wen-Qi Jiang, 2017, Cancer.

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.

Baorui Liu, Changping Wu, Y. Shu, 2016, Experimental and therapeutic medicine.

Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

Yuqing Chen, S. Qin, Qiong Wu, 2012, Oncology reports.

Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications.

Yan Yang, Qiong Wu, R. Zheng, 2014, International journal of clinical and experimental pathology.

A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

Yang Zhang, Y. Ba, T. Deng, 2013, European journal of cancer.